Young Kee Shin

This inventor holds 24 USPTO granted patents and 14 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in Cancer Treatment. Top assignees: Abion Inc., Gencurix Inc, Seoul National University. Active years: 2012-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Young Kee Shin. Retrieved from https://idiyas.com/inventor/young-kee-shin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 14)

% Patents Active = 91.7

CIPO Patents = 4

EPO Patents = 8 (Patent Applications = 23)

Average Co-Inventor Count = 4.7

ph-index = 1

Forward Citations = 6(Granted Patents)

Company Filing History:

Seoul National University

patents

4. 2 out of 2

Logone Bio Convergence Research Foundation

Referncebiolabs, Co., Ltd

patent

9. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

Areas of Expertise:

Interferon

Cancer Therapy

Antibody

Gene Expression

Prognosis Prediction

HPV Infection

Biological Sample

Nucleic Acid Quality

Breast Cancer

cFLIP siRNA

Dendron Conjugate

Tumor Markers

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421297 - Type 1 interferon neutralizing FC-fusion protein and use thereof (2025-09-23),

2. 12377132 - Method for treating or sensitizing interferon beta resistant cancer comprising cFLIP siRNA (2025-08-05),

3. 12173074 - Anti-c-Met agonist antibody and use thereof (2024-12-24),

4. 12098198 - Antibody binding specifically to ECL-2 of claudin 3, fragment thereof, and use thereof (2024-09-24),

5. 11970732 - Method for determining nucleic acid quality of biological sample (2024-04-30),

6. 11840733 - Method for predicting prognosis of breast cancer patient (2023-12-12),

7. 11464832 - Composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA (2022-10-11),

8. 11286296 - Anti-human ninjurin-1 (NINJ-1) antibodies and methods for detecting human NINJ-1 (2022-03-29),

9. 11261482 - Composition for detecting epidermal cell growth factor receptor gene mutation, and kit comprising same (2022-03-01),

10. 11220716 - Methods for predicting the prognosis of breast cancer patient (2022-01-11),

11. 11107552 - Data processing, analysis method of gene expression data to identify endogenous reference genes (2021-08-31),

12. 10806799 - Human interferon-beta variant conjugated immunocytokine and method for preparing same (2020-10-20),

13. 10718030 - Methods for predicting effectiveness of chemotherapy for a breast cancer patient (2020-07-21),

14. 10655187 - Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof (2020-05-19),

15. 10576158 - Immune conjugate having dendron conjugated to antibody and use thereof (2020-03-03),

Title: Young Kee Shin: Pioneering Inventor from Seoul

Introduction: Young Kee Shin is a distinguished inventor hailing from Seoul, South Korea, known for his groundbreaking contributions to various fields.

Latest Patents: Young Kee Shin holds several patents in the areas of technology and healthcare, showcasing his innovative mindset and problem-solving abilities.

Career Highlights: With a career spanning over two decades, Young Kee Shin has worked tirelessly to develop cutting-edge solutions that have revolutionized industries and improved the lives of many.

Collaborations: Throughout his career, Young Kee Shin has collaborated with leading researchers, scientists, and companies to bring his inventions to life, fostering a culture of innovation and excellence.

Conclusion: Young Kee Shin's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a trailblazer in the world of inventions, leaving a lasting impact on society.

Profile summary based on public USPTO records.